Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
#2232
Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.
Aim(s): Evaluate interval reduction of SSAs in progressive NETs in the elderly.
Materials and methods: We evaluated 6 patients with progressive NETs receiving Lanreotide ATG 120 mg/21 days.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Puliafito I, Prestifilippo A, Colarossi C, Giuffrida P, Castorina L,
Keywords: somatostatin, analogs, interval, reduction, experience, elderly,
To read the full abstract, please log into your ENETS Member account.